Atia Vision, A Shifamed Portfolio Company, Closes $10M In Series C Financing
CAMPBELL, Calif., Dec. 10, 2018 -- (Healthcare Sales & Marketing Network) -- Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular accommodating intraocular lens, announced today the c... Devices, Ophthalmology, Venture Capital Atia Vision, Shifamed, intraocular lens (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 10, 2018 Category: Pharmaceuticals Source Type: news

Vast Therapeutics Announces Series A Funding
Partnership with Shionogi Ltd Includes Collaboration for Development of Proprietary Nitric Oxide Powder Technology for Antimicrobial Resistant Bacteria in Respiratory Applications DURHAM, N.C., Dec. 5, 2018 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, Venture Capital Vast Therapeutics, KNOW Bio, nitric oxide, cystic fibrosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 5, 2018 Category: Pharmaceuticals Source Type: news

Tactiva Therapeutics raises $35 million in venture capital; plans to create 45 jobs in Buffalo
A Buffalo-based biotechnology company has raised $35 million with plans to hire up to 45 new employees as it sets to enter human trials. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 4, 2018 Category: Pharmaceuticals Source Type: news

Healthcare Startups Raised $2.2 Billion In November
Venture capital fundraising among healthcare startups was down 25% to $2.18 billion in November compared the same month one year ago, according to an analysis conducted for Forbes by Pitchbook. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 3, 2018 Category: Pharmaceuticals Authors: Michela Tindera, Forbes Staff Source Type: news

Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
Funds will accelerate clinical development of VAR 200, 2-hydroxypropyl-beta-cyclodexrtrin (2HPβCD), for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disease Incon's investment in Variant expands their biopharmaceutical busi... Biopharmaceuticals, Venture Capital, Personnel Variant Pharmaceuticals, Glomerulosclerosis, Alport Syndrome (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 3, 2018 Category: Pharmaceuticals Source Type: news

ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes
Three financing initiatives announced over last three months secure combined commitments of over $100M to drive forward the Company's human cell therapy platform including its clinical-stage islet cell replacement product candidates Initial data from cl... Regenerative Medicine, Endocrinology, Venture Capital ViaCyte, islet replacement, diabetes, PEC-Direct, PEC-Encap (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 29, 2018 Category: Pharmaceuticals Source Type: news

MabVax Therapeutics Holdings, Inc. Announces $1.0 Million Equity Purchase Agreement
SAN DIEGO, Nov. 28, 2018 -- (Healthcare Sales & Marketing Network) -- MabVax Therapeutics Holdings, Inc. (OTC Pink: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the t... Biopharmaceuticals, Oncology, Venture Capital MabVax Therapeutics, monoclonal antibody, pancreatic cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 28, 2018 Category: Pharmaceuticals Source Type: news

Corner Office: Gregg Renfrew of Beautycounter on Toxic Chemicals and Getting Fired by Messenger
Before starting the all-natural personal care business, the New York native worked for Martha Stewart and Susie Hilfiger. (Source: NYT Health)
Source: NYT Health - November 21, 2018 Category: Consumer Health News Authors: DAVID GELLES Tags: Women and Girls Venture Capital Regulation and Deregulation of Industry Hazardous and Toxic Substances Weddings and Engagements Cosmetics and Toiletries Avon Products Inc Beautycounter Estee Lauder Companies Inc Food and Drug Administrat Source Type: news

Jump Technologies raises another $2 million for growth
Jump Technologies Inc., which makes software hospitals use to manage supplies, has closed on $2 million that will got toward ramping up sales and product development, the company said Monday. The capital comes as a follow-on investment to a $3.5 million Series B round the Jump Technologies raised last year. New York-based growth equity firm Black Granite Capital led the round of funding. Mount Sinai Ventures, the venture capital arm of New York-based Mount Sinai Health System, came i n as a new… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 19, 2018 Category: American Health Authors: Katharine Grayson Source Type: news

Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology
Series B financing led by 6 Dimensions Capital, Bessemer Venture Partners, and Pfizer Ventures Financing to enable the advancement of lead program into clinical development and support the progression of additional programs CAMBRIDGE, Mass., Nov. 13,... Biopharmaceuticals, Venture Capital, Personnel Kymera Therapeutics, Pegasus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 13, 2018 Category: Pharmaceuticals Source Type: news

Atlas Ventures startup Kymera Therapeutics lands $65M investment round
Cambridge startup Kymera Therapeutics Inc. has closed a $65 million Series B venture capital round Tuesday that will support the company as it prepares its first cancer and inflammatory disease drugs for the clinic. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - November 13, 2018 Category: Health Management Authors: Allison DeAngelis Source Type: news

Atlas Ventures startup Kymera Therapeutics lands $65M investment round
Cambridge startup Kymera Therapeutics Inc. has closed a $65 million Series B venture capital round Tuesday that will support the company as it prepares its first cancer and inflammatory disease drugs for the clinic. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 13, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Arix Bioscience plc: Arix Participates in Harpoon $70m Series C Investment Round
This Announcement Contains Inside Information Within the Meaning of the EU Market Abuse Regulation No.596/2014 Arix's total interest in Harpoon increases to £20.2 million from £9.4 million Uplift of £4.7 million to Arix's most recen... Biopharmaceuticals, Oncology, Venture Capital Arix Bioscience, TriTAC (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 12, 2018 Category: Pharmaceuticals Source Type: news

Lia DIagnostics raises $2.6M for biodegradable pregnancy test
Lia Diagnostics, the Philadelphia company that has developed a flushable and biodegradable home pregnancy test, raised $2.6 million in a private equity financing. The private stock sale was disclosed in documents the company filed with the Securities and Exchange Commission. Lia is seeking to raise a total of $3 million, according to the financing. Bethany Edwards, Lia co-founder and CEO, said the company’s existing investors along with Pink Ceiling, a N orth Carolina venture capital firm that… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 9, 2018 Category: American Health Authors: John George Source Type: news

Lia Diagnostics raises $2.6M for its flushable & biodegradable pregnancy test
Lia Diagnostics, the Philadelphia company that has developed a flushable and biodegradable home pregnancy test, raised $2.6 million in a private equity financing. The private stock sale was disclosed in documents the company filed with the Securities and Exchange Commission. Lia is seeking to raise a total of $3 million, according to the financing. Bethany Edwards, Lia co-founder and CEO, said the company’s existing investors along with Pink Ceiling, a N orth Carolina venture capital firm that… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - November 9, 2018 Category: Pharmaceuticals Authors: John George Source Type: news

Lia Diagnostics raises $2.6M for its flushable & biodegradable pregnancy test
Lia Diagnostics, the Philadelphia company that has developed a flushable and biodegradable home pregnancy test, raised $2.6 million in a private equity financing. The private stock sale was disclosed in documents the company filed with the Securities and Exchange Commission. Lia is seeking to raise a total of $3 million, according to the financing. Bethany Edwards, Lia co-founder and CEO, said the company’s existing investors along with Pink Ceiling, a N orth Carolina venture capital firm that… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 9, 2018 Category: Biotechnology Authors: John George Source Type: news

Opternative raises $9M to expand Its online vision test business
Chicago eye care tech company Opternative has raised a new round of funding to hire more employees as it grows its online vision test business. Opternative announced Thursday that it raised $9 million in a round led by Trust Ventures, a new, Austin based VC firm, partnered with Koch Industries, that invests in and supports startups facing regulatory challenges. Additionally, Chicago VC firms Pritzker Group Venture Capital and Jump Capital participated in the funding round. This latest financing… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - November 8, 2018 Category: American Health Authors: Katherine Davis Source Type: news

This CEO Is Pushing a Pill For Female Sex Drive. But Does the Science Hold Up?
There are two schools of thought about pink. One is that it is the color of bubble gum and Barbie. Cindy Eckert’s view is that it is the color of business. It is a dominant presence at the offices of her Raleigh, N.C., venture-capital firm, the Pink Ceiling, a fund that advertises its main goal as “to make women really f-cking rich.” It’s an even more dominant presence on Eckert, who defies people to observe the taboo on assessing anyone–especially a woman–by their clothes. She wears some hue of pink every working day, accessorized with hot pink nails, lipstick and shoes. Even her hair s...
Source: TIME: Science - November 8, 2018 Category: Science Authors: Belinda Luscombe Tags: Uncategorized Sex society Source Type: news

This CEO Is Pushing a Pill For Female Sex Drive. But Does the Science Hold Up?
There are two schools of thought about pink. One is that it is the color of bubble gum and Barbie. Cindy Eckert’s view is that it is the color of business. It is a dominant presence at the offices of her Raleigh, N.C., venture-capital firm, the Pink Ceiling, a fund that advertises its main goal as “to make women really f-cking rich.” It’s an even more dominant presence on Eckert, who defies people to observe the taboo on assessing anyone–especially a woman–by their clothes. She wears some hue of pink every working day, accessorized with hot pink nails, lipstick and shoes. Even her hair s...
Source: TIME: Health - November 8, 2018 Category: Consumer Health News Authors: Belinda Luscombe Tags: Uncategorized Sex society Source Type: news

Illumina Shows That Big Medtech Deals Are Far from Over
Just when it looked like the year would end without another mega-merger, Illumina has swooped in to acquire its rival, Pacific Biosciences (PacBio), for $1.2 billion. The move would solidify San Diego, CA-based Illumina’s position in the genetic sequencing market. The acquisition is expected to close in mid-2019. Under the deal, which has been approved by both firms’ boards, Illumina would buy Menlo Park, CA-based PacBio at a price of $8 a share. This price represents a premium of 71% to Pacific Biosciences’ 30 trading day volume weighted average share price as of the m...
Source: MDDI - November 3, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Healthcare Startups Have Raised More This Year Than in 2012 And 2013 Combined
Healthcare venture capital fundraising continued its 10-year high in October, according to an analysis conducted for Forbes by Pitchbook. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 2, 2018 Category: Pharmaceuticals Authors: Michela Tindera, Forbes Staff Source Type: news

1DROP Raises $4.25 Million to Develop Next-Generation Portable Medical Diagnostics
Investment will support commercialization and development of panels of new diagnostic tests BOSTON and NEUCHATEL, Switzerland, Oct. 31, 2018 -- (Healthcare Sales & Marketing Network) -- 1DROP, a life science company developing and commercializing an ea... Diagnostics, Venture Capital 1DROP (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 31, 2018 Category: Pharmaceuticals Source Type: news

Shavit Capital Completes $100 Million Investment Round for Its Fifth Fund
Shavit is one of the leading funds in Israel specializing in pre-IPO investments JERUSALEM, October 31, 2018 -- (Healthcare Sales & Marketing Network) -- Shavit Capital announces the completion of a $100 million funding round for its fifth fund. Founde... Biopharmaceuticals, Devices, Venture Capital Shavit Capital (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 31, 2018 Category: Pharmaceuticals Source Type: news

Carrot raises $25m for tech-enabled smoking cessation program
Digital health company Carrot said today that it raised $25 million to commercialize its tech-enabled Pivot smoking cessation program. The round was led by Johnson & Johnson‘s (NYSE:JNJ) strategic venture capital arm, JJDC. New York Life Ventures and existing investors Khosla Ventures, Marc Benioff, founder Dr. David Utley and R7 Partners also contributed to the financing round. Get the full story at our sister site, Drug Delivery Business News. The post Carrot raises $25m for tech-enabled smoking cessation program appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Featured mHealth (Mobile Health) Pharmaceuticals carrot johnsonandjohnson Source Type: news

89Bio Launches into Liver and Metabolic Disorders with $60 Million Series A Financing
Investment round led by founding investors, OrbiMed Israel and OrbiMed US, and Longitude Capital, with participation by RA Capital Management and Pontifax Company acquires NASH assets from Teva, initiates Phase 1 clinical trial Rohan Palekar, former ... Biopharmaceuticals, Venture Capital, Personnel 89Bio, nonalcoholic steatohepatitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2018 Category: Pharmaceuticals Source Type: news

Cincinnati firm lands $40M venture capital investment
Enable Injections disclosed today that the company has completed a first closing of a Series B round that raised more than $40 million, one of the largest investments in a Cincinnati company ever made by venture capitalists.   Evendale-based Enable said the investment was led by Sanofi-Sunrise, the Massachusetts venture capital arm of the Paris-based Sanofi pharmaceutical company. It's the world's third-largest pharma firm based on sales of $39.5 billion. “I have a big smile on my face,” said… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 25, 2018 Category: Biotechnology Authors: Barrett J. Brunsman Source Type: news

K4Connect scores $12M, investment from AXA Venture Partners
K4Connect scored another $12 million in Series B of its funding round, bringing its total to $22 million. Scott Moody, K4Connect co-founder and CEO, said the funding round was led by AXA Venture Partners – the venture capital fund of AXA, one of the largest global insurance companies. He said no other new investors were involved in the series, and that the $12 million was raised solely from AXA and existing partners. The exact amount AXA invested was not disclosed. Moody said the new funding… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 24, 2018 Category: American Health Authors: Seth Gulledge Source Type: news

K4Connect scores $12M, investment from AXA Venture Partners
K4Connect scored another $12 million in Series B of its funding round, bringing its total to $22 million. Scott Moody, K4Connect co-founder and CEO, said the funding round was led by AXA Venture Partners – the venture capital fund of AXA, one of the largest global insurance companies. He said no other new investors were involved in the series, and that the $12 million was raised solely from AXA and existing partners. The exact amount AXA invested was not disclosed. Moody said the new funding… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 24, 2018 Category: Biotechnology Authors: Seth Gulledge Source Type: news

A Truly Epic CEO Rocks the Cleveland Medical Innovation Summit
When Judy Faulkner launched Epic Systems from a Wisconsin basement in 1979, the medical software company was worth about $70,000. Speaking at the Cleveland Clinic Medical Innovation Summit, Faulkner told the audience about the firm's "Epic" journey.  According to Forbes, Faulkner has come a long way since founding the company. The CEO now has  a net worth of about $3.5 billion and is the third richest self-made woman on Forbes' list. Epic specializes in electronic health records and had sales of $2.7 billion in 2017. “When we started, we had about ...
Source: MDDI - October 24, 2018 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Source Type: news

Gauss Uses AI to Accurately Measure Blood Loss
Gauss Surgical is using machine learning and artificial intelligence for the early recognition of postpartum hemorrhage. To do this, the Los Altos, CA-based company has developed Triton, a monitoring solution that helps physicians and clinicians accurately estimate blood loss in real-time. The company has received a nod from FDA for Triton and has raised $20 million in a series C round to help push adoption for the solution. “The proceeds are primarily to accelerate the commercial entry of [Triton] and its expansion,” Siddarth Satish, founder and CEO of Gauss Surgical, told MD+DI. â...
Source: MDDI - October 17, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Imaging Source Type: news

Gauss raises $20 million in Series C from Northwell Health and SoftBank Ventures Korea for AI-Enabled Platform for the Operating Room
The company's iPad-based Triton platform uses digital imaging and Artificial Intelligence (AI) to address preventable maternal death and health complications in childbirth and surgery: Potential to revolutionize the operating room using Computer Vision ... Devices, Surgery, Monitoring, Venture Capital Gauss Surgical, Triton, blood loss monitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 17, 2018 Category: Pharmaceuticals Source Type: news

What Could the Midterm Elections Mean for Medtech?
Speakers at The Medtech Conference from AdvaMed shared their thoughts about the midterm elections in “DC Download and Midterms Preview,” moderated by Greg Crist, executive vice president, public affairs, AdvaMed. The panel included Charlie Dent, former U.S. representative and now senior policy advisor for DLA Piper; Walt Rosebrough, president and CEO of STERIS Corp.; Elizabeth Pika Sharp, senior vice president and managing director, federal government affairs, at AdvaMed; and Jennifer Nieto, vice president, federal government relations and alliance development, California Life Sciences A...
Source: MDDI - October 12, 2018 Category: Medical Devices Authors: Daphne Allen Tags: Business Source Type: news

Glympse Bio raises $22M for disease-detecting sensors
Sensor-driven disease detection company Glympse Bio has raised $22 million in a Series A round to fund clinical trials for its technology. The Cambridge, Mass.-based company uses bioengineered activity sensors transported to the site of disease in patients to investigate biological targets such as proteases – a class of enzymes that drive critical disease pathways. Once a disease is located, the sensor emits a signal that can be detected noninvasively from the recipient’s urine, according to the company. A spinout from Massachusetts Institute of Technology, Glympse Bio is applying machine learnin...
Source: Mass Device - October 10, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Bioelectronic Medicine Blog Business/Financial News Diagnostics Featured Funding Roundup Research & Development glympsebio Massachusetts Institute of Technology Source Type: news

Report: Corporate venture capital is catalyzing groundbreaking biomedical innovation in the United States
Venture capital is increasingly becoming the growing force for financing biotech and other startups, fueling medical advances in the U.S. A new report released today from TEConomy, examines the role and impact of one specific player in that ecosystem: biopharmaceutical corporate venture capital (CVC) funds, which often support early stage medical innovation. (Source: The Catalyst)
Source: The Catalyst - October 10, 2018 Category: Pharmaceuticals Authors: Anne McDonald Pritchett, PhD Tags: Research and Development Source Type: news

Report: Drug delivery investments down in Q3
Investment spending in the drug delivery sector has dropped significantly for the third quarter, but is staying ahead of last years numbers for the first through third quarters, according to a new report. Venture capital investments fell a significant 61.8% to $29.6 million during the three months ended September 30, though deal volume stayed the same when compared to the third quarter of 2017, according to the MoneyTree report from PricewaterhouseCoopers and CB Insight. Read the whole story on our sister site, Drug Delivery Business News The post Report: Drug delivery investments down in Q3 appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 9, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Wall Street Beat CB Insights PricewaterhouseCoopers (PwC) Venture Capital/Private Equity Source Type: news

Arizona startups raised $70.5 million in venture capital last quarter
Ten companies raised $1 million or more in the third quarter. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 9, 2018 Category: American Health Authors: Hayley Ringle Source Type: news

Colorado on track to surpass 2015 record of venture capital investments
The Denver and Boulder metros saw increases in venture capital funding compared to the third quarter last year. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 9, 2018 Category: Biotechnology Authors: Monica Vendituoli Source Type: news

Report: Medical device deal volume, spend down during Q3
Investors spent less money on fewer deals in the medical device sector during the third quarter and so far this year, bucking the overall growth trend for venture capital-backed firms, according to a new report. Venture capital investment fell -19.7% to $772.7 million during the three months ended Sept. 30, with deal volume down -20.3% to 51 deals during the quarter, according to the MoneyTree report from PricewaterhouseCoopers and CB Insight. Year-to-date, VCs put $2.32 billion into 172 deals, down -11.4% and -16.1%, respectively, compared with the first three quarters of 2017, according to the report. Medtech’s per...
Source: Mass Device - October 9, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Featured Funding Roundup Wall Street Beat CB Insights PricewaterhouseCoopers (PwC) Venture Capital/Private Equity Source Type: news

Colorado on track to surpass 2015 record of venture capital investments
The Denver and Boulder metros saw increases in venture capital funding compared to the third quarter last year. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 9, 2018 Category: American Health Authors: Monica Vendituoli Source Type: news

Arizona startups raised $70.5 million in venture capital last quarter
Ten companies raised $1 million or more in the third quarter. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 9, 2018 Category: American Health Authors: Hayley Ringle Source Type: news

Arizona startups raised $70.5 million in venture capital last quarter
Ten companies raised $1 million or more in the third quarter. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 9, 2018 Category: Biotechnology Authors: Hayley Ringle Source Type: news

CSA Medical Secures $23 Million to Advance its Cryospray(TM) Therapies for Esophageal Disease and COPD
Financing to Support Expansion of CSA's truFreeze® Spray Cryotherapy Business for Esophageal Disease and Launch of the Reo Radial Catheter in 2019 for Barrett's Esophagus Also Supports CE Mark and Pivotal Clinical Study Launch for RejuvenAir® Sp... Devices, Venture Capital CSA Medical, Cryospray, RejuvenAir, Esophageal Disease, COPD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 8, 2018 Category: Pharmaceuticals Source Type: news

Form D Friday: Denver venture capital fund issued $12 million
Form D Friday is a weekly Denver Business Journal feature. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - October 5, 2018 Category: Health Management Authors: Monica Vendituoli Source Type: news

Form D Friday: Denver venture capital fund issued $12 million
Form D Friday is a weekly Denver Business Journal feature. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 5, 2018 Category: Biotechnology Authors: Monica Vendituoli Source Type: news

Arix Bioscience plc Co-leads $58 Million Series A Investment Round for VelosBio
Arix co-leads a $58 million Series A investment in new Group Business, VelosBio Inc., bringing core portfolio[1] to 15 companies Arix commits $11 million (£8.4 million)[2] for 11.2% ownership stake Co-investment with strategic partner Takeda an... Biopharmaceuticals, Oncology, Venture Capital, Personnel Arix Bioscience, VelosBio (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 1, 2018 Category: Pharmaceuticals Source Type: news

Sloan Kettering ’ s Cozy Deal With Start-Up Ignites a New Uproar
A for-profit venture with exclusive rights to use the center ’ s vast archive of tissue slides has generated concerns at the nonprofit cancer center. (Source: NYT Health)
Source: NYT Health - September 20, 2018 Category: Consumer Health News Authors: CHARLES ORNSTEIN and KATIE THOMAS Tags: Artificial Intelligence Tissue (Human) Conflicts of Interest Hospitals Baselga, Jose Venture Capital Federal Taxes (US) Nonprofit Organizations Memorial Sloan-Kettering Cancer Center Paige.AI David Klimstra Thomas Fuchs Norman Selb Source Type: news

Former Obama administration official Slavitt's VC fund raises $115M
The venture capital firm started by former Obama administration official and ex-Optum executive Andy Slavitt has closed on $115 million for its first fund. Town Hall Ventures, which has offices in Minneapolis and New York, also announced new investments in several startups Thursday, including Minneapolis-based insurer Bright Health Inc. and home-care services company Landmark Health. It did not disclose the size of those investments. Town Hall, whic h backs startups that target underserved populations,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 20, 2018 Category: Biotechnology Authors: Katharine Grayson Source Type: news

Providence Medical Technology Secures $25 Million In Equity Financing
Proceeds to Bolster Commercial Expansion & Clinical Development of its DTRAX® Spinal System PLEASANTON, Calif., Sept. 20, 2018 -- (Healthcare Sales & Marketing Network) -- Providence Medical Technology, Inc., an innovator in tissue-sparing surgical... Devices, Orthopaedic, Neurosurgery, Venture Capital Providence Medical Technology, DTRAX Spinal System, cervical fusion (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 20, 2018 Category: Pharmaceuticals Source Type: news

Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure
LISLE, Ill., Sept. 14, 2018 -- (Healthcare Sales & Marketing Network) -- Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the close of a Series D financing round totaling $45 millio... Devices, Cardiology, Venture Capital Endotronix, Cordella, Heart Failure System, wireless, pulmonary artery sensor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 14, 2018 Category: Pharmaceuticals Source Type: news

CASI Pharmaceuticals Announces $48.5 Million Private Placement
ROCKVILLE, Md., Sept. 14, 2018 -- (Healthcare Sales & Marketing Network) -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the development and delivery of high quality, cost-effective pharmaceutical products and innova... Biopharmaceuticals, Venture Capital CASI Pharmaceuticals, Spectrum Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 14, 2018 Category: Pharmaceuticals Source Type: news